USPTO serial 79378238
HERNEXEOS
Reviewed by CopyMark Law Group
Reg. 7628763Status 790Registered
- Filing date
- Status date
- Registration date
- Dec 31, 2024
- Examiner
- O'BRIEN, JENNIFER LYNN
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with HERNEXEOS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Boehringer Ingelheim International GmbH
DE
Other trademarks owned by Boehringer Ingelheim International GmbH
Boehringer Ingelheim International GmbH
DE
Other trademarks owned by Boehringer Ingelheim International GmbH
Boehringer Ingelheim International GmbH
DE
Other trademarks owned by Boehringer Ingelheim International GmbH
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
MAURY M TEPPER III
MAURY M TEPPER III TEPPER & EYSTER PLLC3724 BENSON DRRALEIGH, NC 27609UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the prevention and treatment of diseases and disorders of the alimentary tract and metabolism; pharmaceutical preparations for the prevention and treatment of diseases and disorders and of the blood and blood forming organs; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system; pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, damaged skin and tissues; pharmaceutical preparations for the prevention and treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the prevention and treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment and prevention of hormonal diseases and disorders; pharmaceutical preparations for the treatment and prevention of infectious diseases and disorders and viral infections; pharmaceutical preparations for the prevention and treatment of oncological and auto-immune diseases and disorders; pharmaceutical preparations, namely, cell based immune therapeutics for treatment of cancer, for treatment of immunological diseases, and treatment of infectious diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Boehringer Ingelheim International GmbH
- Other trademarks owned by Boehringer Ingelheim International GmbH
- Other trademarks owned by Boehringer Ingelheim International GmbH
- Other trademarks in Class 005
- Similar marks named HERNEXEOS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 27, 2026 | PETC | CANCELLATION INSTITUTED NO. 999999 | — |
| Jul 11, 2025 | FINV | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 24, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jun 24, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 31, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 1, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 10, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 8, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Dec 31, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 31, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 12, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 12, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 23, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 1, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 26, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 26, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 26, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 24, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 29, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 29, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 12, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 11, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 9, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 19, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 15, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 13, 2023 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Sep 7, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |